ASSESSMENT OF THE EFFICACY OF VEGF DRUGS IN THE TREATMENT OF DIABETIC RETINOPATHY
Mahmudov Narzikul Xodjanazarovich , Termez Branch of the Republican Specialized Center of Scientific Applied Medicine of Fall Microsurgery, UzbekistanAbstract
Aims: This study aims to compare the effectiveness of treatment between anti-vascular endothelial growth factor (anti-VEGF) agents in diabetic macular edema (DME) patients with disorganization of retinal inner layers (DRIL). Epiretinal membrane, serous macular detachment, ellipsoid zone (EZ) disorder, external limiting membrane (ELM) disorder, and hyperreflective foci were also examined.
Methods: Patients treated for DME and also had DRIL were included in the study. The study design was retrospective and cross-sectional. The complete ophthalmologic records and imaging were scanned at the beginning, 3rd-month, 6th-month, and 12th-month follow-up, and the treatments administered were recorded. Anti-VEGF agents administered to the patients were examined in three groups: bevacizumab, ranibizumab, and aflibercept.
Keywords
The effectiveness of treatment, The study design, and cross-sectional
References
Shaw JE et al (2010) Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 87(1):4–14 - DOI - PubMed
Guariguata L et al (2014) Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 103(2):137–149 - DOI - PubMed
Wong TY et al (2016) Diabetic retinopathy. Nat Rev Dis Primers 2(1):16012 - DOI - PubMed
Fenwick E et al (2011) The impact of diabetic retinopathy: understanding the patient’s perspective. Br J Ophthalmol 95(6):774–782 - DOI - PubMed
Mohamed Q, Gillies MC, Wong TYJJ (2007) Management of diabetic retinopathy: a systematic review. JAMA 298(8):902–916 - DOI - PubMed
Article Statistics
Downloads
Metrics
Copyright License
Copyright (c) 2024 Mahmudov Narzikul Xodjanazarovich
This work is licensed under a Creative Commons Attribution 4.0 International License.
Individual articles are published Open Access under the Creative Commons Licence: CC-BY 4.0.